Spots Global Cancer Trial Database for Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Official Title: Positron Emission Tomography Pre- and Post-treatment Assessment For Locally Advanced Non-Small Cell Lung Carcinoma
Study ID: NCT00083083
Conditions
Study Description
Brief Summary: RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Detailed Description: OBJECTIVES: Primary * Determine whether peak standardized uptake value (SUV) for fludeoxyglucose F 18 positron emission tomography (FDG-PET) shortly after definitive chemoradiotherapy is predictive of long-term survival of patients with inoperable stage IIB or III non-small cell lung cancer. Secondary * Determine whether max SUV for FDG-PET shortly after definitive chemoradiotherapy is predictive of long-term survival in these patients. * Determine whether post-treatment imaging using peak and max SUV for FDG-PET shortly after definitive chemoradiotherapy is predictive of local disease control in these patients. * Determine whether pre-treatment imaging using these techniques is predictive of long-term survival and local disease control in these patients. * Correlate, if possible, Ki-67 expression with overall survival of patients assessed with these imaging techniques. OUTLINE: This is a diagnostic, multicenter study. Before starting chemoradiotherapy, patients undergo baseline whole-body positron emission tomography (PET) imaging. Patients receive fludeoxyglucose F 18 (\^18FDG) IV followed 50-70 minutes later by PET imaging. Patients then receive concurrent definitive radiotherapy and chemotherapy. Patients enrolled in other treatment-oriented clinical trials receive therapy as per that trial. Other patients receive standard thoracic radiotherapy (dose ≥ 60 Gy) and standard chemotherapy comprising a platin (cisplatin or carboplatin) and a second non-platin, non-gemcitabine drug (etoposide, vinblastine, vinorelbine, paclitaxel, or docetaxel). Approximately 14 weeks after completion of chemoradiotherapy and adjuvant chemotherapy (if given), patients undergo post-treatment \^18FDG-PET imaging. Patients are followed every 3 months for 2 years and then every 6 months for at least 1 year. PROJECTED ACCRUAL: A total of 250 patients (including at least 75 with stage IIB/IIIA disease and at least 75 with stage IIIB disease) will be accrued for this study within 2 years.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
Scottsdale Medical Imaging, Limited, Scottsdale, Arizona, United States
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Radiological Associates of Sacramento Medical Group at Sutter Cancer Center, Sacramento, California, United States
Hospital of Saint Raphael, New Haven, Connecticut, United States
Bethesda Comprehensive Cancer Care Center at Bethesda Memorial Hospital, Boynton Beach, Florida, United States
North Broward Medical Center, Dearfield Beach, Florida, United States
Integrated Community Oncology Network at Baptist Cancer Institute, Jacksonville, Florida, United States
Tallahassee Memorial Hospital, Tallahassee, Florida, United States
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States
Saint John's Cancer Center at Saint John's Medical Center, Anderson, Indiana, United States
Center for Cancer Care at Goshen General Hospital, Goshen, Indiana, United States
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Dana-Farber Partners Cancer Care, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
South Shore Hospital, South Weymouth, Massachusetts, United States
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
West Michigan Cancer Center, Kalamazoo, Michigan, United States
William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
Mallinckrodt Institute of Radiology at Washington University Medical Center, St. Louis, Missouri, United States
Renown Institute for Cancer at Renown Regional Medical Center, Reno, Nevada, United States
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Sister Patricia Lynch Regional Cancer Center at Holy Name Hospital, Teaneck, New Jersey, United States
J. Phillip Citta Regional Cancer Center at Community Medical Center, Toms River, New Jersey, United States
McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States
Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States
UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
Lankenau Cancer Center at Lankenau Hospital, Wynnewood, Pennsylvania, United States
Roger Williams Medical Center, Providence, Rhode Island, United States
Brown University School of Medicine, Providence, Rhode Island, United States
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
Bon Secours Cancer Institute at St. Mary's Hospital, Richmond, Virginia, United States
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States
Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada
Grand River Regional Cancer Centre at Grand River Hospital, Kitchner, Ontario, Canada
National Cancer Center - Korea, Goyang, , Korea, Republic of
Contact Details
Name: Mitchell Machtay, MD
Affiliation: Sidney Kimmel Cancer Center at Thomas Jefferson University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
